William D. Figg

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

Howard I. Scher, Susan Halabi, Ian F. Tannock et al. · Journal of Clinical Oncology · 2008 · 2.2K citations · Full text

Medicine, Oncology, Urology +17

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Victor Sandor, Susan Bakke, Robert W. Robey et al. · PubMed · 2002 · 510 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +12

Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas

Howard A. Fine, William D. Figg, Kurt A. Jaeckle et al. · Journal of Clinical Oncology · 2000 · 426 citations

Medicine, Oncology, Pharmacology +15

Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer

William L. Dahut, James L. Gulley, Philip M. Arlen et al. · Journal of Clinical Oncology · 2004 · 350 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis <i>In vitro</i> and <i>In vivo</i>

Joell J. Gills, Jaclyn LoPiccolo, Junji Tsurutani et al. · Clinical Cancer Research · 2007 · 326 citations

Medicine, Oncology, Pharmacology +17